Early treatment study
et al., medRxiv, doi:10.1101/2020.06.19.20136093 (Preprint)
Efficacy and safety of ch loroquine or hydroxych loroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
Significantly faster clinical recovery and shorter time to RNA negative (from 7.0 days to 2.0 days (HC
Q), p=0.01. 67 patients with mild/moderate cases.
Please send us corrections, updates, or comments.